Cargando…

MRD Tailored Therapy in AML: What We Have Learned So Far

Acute myeloid leukemia (AML) is a heterogeneous clonal disease associated with a dismal survival, partly due to the frequent occurrence of relapse. Many patient- and leukemia-specific characteristics, such as age, cytogenetics, mutations, and measurable residual disease (MRD) after intensive chemoth...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ngai, Lok Lam, Kelder, Angèle, Janssen, Jeroen J. W. M., Ossenkoppele, Gert J., Cloos, Jacqueline
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2021
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7871983/ https://www.ncbi.nlm.nih.gov/pubmed/33575214 http://dx.doi.org/10.3389/fonc.2020.603636

Ejemplares similares

AML/Normal Progenitor Balance Instead of Total Tumor Load (MRD) Accounts for Prognostic Impact of Flowcytometric Residual Disease in AML
por: Hanekamp, Diana, et al.
Publicado: (2021)

P448: PROGNOSTIC SIGNIFICANCE OF MEASURABLE RESIDUAL DISEASE DETECTION BY FLOW CYTOMETRY IN AUTOLOGOUS STEM CELL APHERESIS PRODUCTS OF PATIENTS WITH AML
por: Tettero, Jesse, et al.
Publicado: (2023)

Prognostic Significance of Measurable Residual Disease Detection by Flow Cytometry in Autologous Stem Cell Apheresis Products in AML
por: Tettero, Jesse M., et al.
Publicado: (2023)

MRD in AML: The Role of New Techniques
por: Voso, Maria Teresa, et al.
Publicado: (2019)

COVID-19: What We Have Learned So Far
por: Clifford, Theresa
Publicado: (2020)

Pediatric Myocarditis: What Have We Learnt So Far?
por: Pomiato, Elettra, et al.
Publicado: (2022)

The hypocretins and the reward function: what have we learned so far?
por: Boutrel, Benjamin, et al.
Publicado: (2013)

Brain Tumor Immunotherapy: What have We Learned so Far?
por: Van Gool, Stefaan Willy
Publicado: (2015)

Editorial: Cancer Nanotheranostics: What Have We Learned So Far?
por: Conde, João, et al.
Publicado: (2016)

OMICs in Cariology and Endodontology – what have we learned so far?
por: Zaura, Egija
Publicado: (2017)

Circadian Clocks in Fish—What Have We Learned so far?
por: Frøland Steindal, Inga A., et al.
Publicado: (2019)

Offline: COVID-19—what have we learned so far?
por: Horton, Richard
Publicado: (2020)

What have we learnt so far from COVID-19?
por: Doherty, Peter C.
Publicado: (2021)

Bleeding in COVID Patients: What We Have Understood So Far
por: Lucatelli, Pierleone, et al.
Publicado: (2021)

Ovarian Cancer Radiosensitivity: What Have We Understood So Far?
por: Barcellini, Amelia, et al.
Publicado: (2022)

ECMO Retrieval Program: What Have We Learned So Far
por: Krasivskyi, Ihor, et al.
Publicado: (2023)

COVID-19 and the heart: what we have learnt so far
por: Shaha, Kunal Bikram, et al.
Publicado: (2020)

Maturation State-Specific Alternative Splicing in FLT3-ITD and NPM1 Mutated AML
por: Wojtuszkiewicz, Anna, et al.
Publicado: (2021)

Campylobacter Phage Isolation and Characterization: What We Have Learned So Far
por: Jäckel, Claudia, et al.
Publicado: (2019)

Editorial: Cancer Epidemiology in China: What We Have Learnt So Far?
por: Chen, Tianhui, et al.
Publicado: (2020)

Sarcopenia in chronic kidney disease: what have we learned so far?
por: Sabatino, Alice, et al.
Publicado: (2020)

What we know so far
Publicado: (2021)

MRD in Venetoclax-Based Treatment for AML: Does it Really Matter?
por: Bernardi, Massimo, et al.
Publicado: (2022)

Normal Hematopoietic Stem Cells within the AML Bone Marrow Have a Distinct and Higher ALDH Activity Level than Co-Existing Leukemic Stem Cells
por: Schuurhuis, Gerrit J., et al.
Publicado: (2013)

Pneumococcal vaccination: what have we learnt so far and what can we expect in the future?
por: Torres, A., et al.
Publicado: (2014)

Toxicity and cellular uptake of gold nanoparticles: what we have learned so far?
por: Alkilany, Alaaldin M., et al.
Publicado: (2010)

Neural synchrony within the motor system: what have we learned so far?
por: van Wijk, Bernadette C. M., et al.
Publicado: (2012)

NEO adjuvant chemotherapy in breast cancer: What have we learned so far?
por: Raut, Nirmal V, et al.
Publicado: (2010)

Combining inclusive and exclusive data analyses-what have we learned so far?
por: Kittel, E W
Publicado: (1973)

Theory: Historical perspective and what have we learned from the Higgs so far
por: Ellis, Jonathan R.
Publicado: (2022)

Interaction between Insects, Toxins, and Bacteria: Have We Been Wrong So Far?
por: Tetreau, Guillaume
Publicado: (2018)

Helping children with reading difficulties: some things we have learned so far
por: McArthur, Genevieve, et al.
Publicado: (2017)

Mitochondrial Neurogastrointestinal Encephalomyopathy: Into the Fourth Decade, What We Have Learned So Far
por: Pacitti, Dario, et al.
Publicado: (2018)

The COVID-19 Pandemic and Cardiovascular Complications: What Have We Learned So Far?
por: Walsh, Mary Norine, et al.
Publicado: (2020)

Gene Therapy in Rare Respiratory Diseases: What Have We Learned So Far?
por: Bañuls, Lucía, et al.
Publicado: (2020)

More on the MORE Life Experience Model: What We Have Learned (So Far)
por: Glück, Judith, et al.
Publicado: (2018)

Role of Gut Dysbiosis in Liver Diseases: What Have We Learned So Far?
por: Fukui, Hiroshi
Publicado: (2019)

Proteomics of Rice—Magnaporthe oryzae Interaction: What Have We Learned So Far?
por: Meng, Qingfeng, et al.
Publicado: (2019)

Implementation of the Nagoya Protocol in Livestock Sector: What Have We Learnt So Far?
por: Martyniuk, Elzbieta, et al.
Publicado: (2021)

Feline Morbillivirus Infection in Domestic Cats: What Have We Learned So Far?
por: De Luca, Eliana, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_8hqad25ijad90kk2bo7mk949mn